BCL2 and breast cancer: Levobupivacaine inhibited proliferation and promoted apoptosis in BC cells.Levobupivacaine after a 24 h treatment significantly decreased in the invasion ability of MCF-7 and MDA-MB-231 cells in a dose-dependent manner.Findings demonstrated a significantly increase of BAX expression and were associated with a decreased of BCL-2 expression and inhibition of PI3K/Akt/mTOR signalling pathway.